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Abstract A potential new treatment for drug addiction is
immunization with vaccines that induce antibodies that can
abrogate the addictive effects of the drug of abuse. One of the
challenges in the development of a vaccine against drugs of
abuse is the availability of an optimum procedure that gives
reproducible and high yielding hapten-protein conjugates. In
this study, a heroin/morphine surrogate hapten (MorHap) was
coupled to bovine serum albumin (BSA) using maleimide-
thiol chemistry. MorHap-BSA conjugates with 3, 5, 10, 15,
22, 28, and 34 haptens were obtained using different linker
and hapten ratios. Using this optimized procedure, MorHap-
BSA conjugates were synthesized with highly reproducible
results and in high yields. The number of haptens attached to
BSA was compared by 2,4,6-trinitrobenzenesulfonic acid
(TNBS) assay, modified Ellman’s test and matrix assisted
laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOFMS). Among the three methods, MALDI-TOF
MS discriminated subtle differences in hapten density. The
effect of hapten density on enzyme-linked immunosorbent
assay (ELISA) performance was evaluated with seven
MorHap-BSA conjugates of varying hapten densities, which
were used as coating antigens. The highest antibody binding
was obtained with MorHap-BSA conjugates containing 3–5
haptens. This is the first report that rigorously analyzes, opti-
mizes and characterizes the conjugation of haptens to proteins
that can be used for vaccines against drugs of abuse. The effect
of hapten density on the ELISA detection of antibodies against
haptens demonstrates the importance of careful characteriza-
tion of the hapten density by the analytical techniques
described.
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Introduction
Addictive drug abuse is a major socially disruptive problem
that has a large impact on society and causes a drain on
medical, economic, and political systems [1]. There is an
estimated 16.5 million people worldwide who use opiates,
with the highest prevalence reported in Southwest and Central
Asia, Eastern-Southeastern Europe, and North America [2].
Development of vaccines for substance abuse represents a
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novel approach to conventional therapy. Vaccines to drugs of
abuse function by producing circulating antibodies, which
bind the drug and prevent it from crossing the blood-brain
barrier. This blocks the drug from entering the brain where the
drug’s euphoric and addictive effects are induced as a result of
interaction with an opiate receptor. Drugs of abuse are small
molecules and do not induce antibodies following injection or
inhalation. Surrogate compounds (haptens) must be attached
to protein molecules (carriers) to be used as immunogens to
produce antibodies to the hapten [3, 4]. In this study, MorHap,
a heroin/morphine hapten, was used as a model hapten to
optimize its attachment to a carrier protein, bovine serum
albumin (BSA). Recently, MorHap was attached to tetanus
toxoid (TT) and used as a candidate vaccine that induced high
titer antibodies, which reacted with heroin and its metabolites,
6-acetylmorphine and morphine, and protected mice from
heroin challenge in an antinociception assay [5, 6].
Common carrier proteins that are usually employed in the
preparation of hapten-protein conjugates are BSA, diphtheria
toxoid (DT), keyhole limpet hemocyanin (KLH), and TT
[5–10]. Haptens can be coupled to protein carriers using
numerous protein modification strategies [11]. Generally, the
choice of conjugation strategy depends on the presence of
intrinsic functional groups in the proteins and haptens. The
carbodiimide reaction is a popular conjugation strategy for
introducing haptens on carriers because surface lysines are
ubiquitous in proteins. Carbodiimide chemistry, however, is
prone to promote oligomerization due to intermolecular reac-
tions of surface lysines and glutamate/aspartate groups. Pro-
tein oligomers are usually insoluble in aqueous solutions and
are difficult to characterize. The maleimide-thiol chemistry
was employed to circumvent the issue of oligomerization
[12]. This coupling chemistry utilizes a heterobifunctional
linker with N-hydroxysuccinimide (NHS) ester on one end
for coupling to surface lysines and maleimide functionality on
the other end for coupling to thiols. Unlike carbodiimide, the
maleimide-thiol chemistry tends not to yield higher protein
aggregates because thiols in proteins are predominantly in an
oxidized state and cysteine residues are less abundant in
proteins compared to lysine residues [13]. Recently, thiolated
haptens and maleimide-conjugated proteins as carriers are
becoming more frequently used for the synthesis of vaccines
against drugs of abuse [5–7, 9, 10].
In general, the chemical structure of the hapten and the
hapten density (number of covalently attached haptens per
molecule of the carrier protein) are critical for the generation
of effective antibody titers. For heroin vaccines, heroin-like
haptens with varying stabilities at physiological pH and
morphine-like haptens have been reported [5, 6, 9]. MorHap,
a heroin/morphine-like hapten, is particularly interesting be-
cause it has been shown to induce high antibody titers [5, 6].
Recently, the effect of hapten density on the immune response
has been demonstrated for a methamphetamine vaccine [7],
but the effect of hapten density on the ELISA coating antigen,
or for opiate vaccines, has not been studied.
Hapten density has often been mediated by coupling chem-
istry strategies, stoichiometry of the reacting partners, and the
nature of the carrier protein [12]. The hapten density has been
assessed by direct and indirect methods. Direct methods have
measured changes in the original protein properties, such as UV
absorption, fluorescence, and mass. If the hapten is a stronger
chromophore than the aromatic residues of the protein, the
number of haptens can be measured by changes in
absorbance/fluorescence. Since these spectrophotometric tech-
niques do not account for the noncovalent binding of the
haptens to the protein, absorbance/fluorescence measurements
can overestimate hapten density. Gel electrophoresis andmatrix
assisted laser desorption ionization time-of-flight mass spec-
trometry (MALDI-TOF MS) are direct methods of assessing
hapten density because they measure changes in mass before
and after conjugation [14, 15]. In contrast to MALDI-TOFMS,
gel electrophoresis cannot discriminate subtle differences in
mass. Quantifying the number of haptens attached to complex
proteins by direct methods is a challenging task. Pryde and
coworkers used a labor-intensive reversed phase HPLC analy-
sis of acid-hydrolyzed hapten-DT conjugates to measure the
number of haptens [8]. Their approach, however, is not suitable
for haptens that degrade at low pH. Unsuccessful measure-
ments of hapten density by conventional MALDI-TOF MS
have been also reported for heroin/morphine-KLH conjugates
[9, 16]. With the latest developments on high mass MALDI-
TOF MS, characterization of these complex conjugates might
be possible in the future [17–19].
2,4,6-Trinitrobenzene sulfonic acid (TNBS), which reacts
with free amines, is a traditional indirect method for assessing
hapten density in proteins [20–22]. The amount of surface
lysines decreases after conjugation. The difference in the num-
ber of amines before and after coupling reactions is correlated
to hapten density. The modified Ellman’s test is also an indirect
method of measuring hapten density for conjugates that were
synthesized using maleimide-thiol coupling chemistry [23].
The modified Ellman’s test measures the amount of maleimide
in the activated BSA intermediate. Maleimide number is equiv-
alent to the number of haptens, because there is a 1:1 stoichi-
ometry betweenmaleimide and thiolated haptens [12]. Both the
TNBS assay andmodified Ellman’s test measure the number of
reactive functional groups and are a measure of “hapten equiv-
alences” and not hapten density per se. Therefore, an optimum
procedure must be developed to ensure that hapten equiva-
lences correspond to hapten density.
Another consideration for vaccine development that is
concomitant with hapten density is the protein yield of the
synthesized conjugates. For future use as a licensed vaccine,
efforts must be invested to optimize the yield of hapten-
protein conjugates. Despite the relevance of hapten density
and protein yield in vaccine development, the quantitative
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relationship between the two components has not been inves-
tigated. This is most likely due to the lack of optimized
coupling protocol that gives reproducible hapten-protein con-
jugates. In the present study, the conjugation of MorHap to
BSAwas optimized using appropriate linker and hapten ratios
to BSA. The effect of MorHap density on BSAwas tested as a
coating antigen in an ELISA to measure antibodies to
MorpHap, which yielded the surprising result that highest
antibody binding was obtained with the least amount of at-
tached haptens.
Materials and methods
BSA, used for coupling to MorHap, NHS-(PEG)2-maleimide
linker (SM-(PEG)2), spin desalting column (Zeba, 7K molec-
ular weight cut-off (MWCO)), dialysis cassettes (Slide-A-
Lyzer G2, 10K MWCO), bicinchoninic acid (BCA) protein
assay kit, phosphate buffered saline (PBS, 100 mM sodium
phosphate, 150 mM NaCl, pH 7.2) that was used for the
coupling reaction, and ultrapure 10 % sodium dodecyl sulfate
(SDS) were purchased from Pierce Protein Research/Thermo
Fisher Scientific (Rockford, IL). Trifluoroacetic acid (TFA),
triisopropylsilane (TIS), dimethylsulfoxide (DMSO), 5,5′-
dithiobis(2-nitrobenzoic acid) (Ellman’s reagent), sodium 2-
mercaptoethanesulfonate (MESNA), L-glutamic acid,
sinapinic acid, UV-transparent 96-well plates, mass spectrom-
etry grade formic acid (FA), BSA that was used as MALDI-
TOF calibration standard and BSA that was used as blocking
reagent for ELISAwere purchased from Sigma-Aldrich (Saint
Louis, MO). TNBS was purchased from G-Biosciences (St.
Louis, MO). ZipTip (C4 resin) was purchased from Millipore
(Billerica, MA). Polysulfone membrane filter (0.22 μm) was
purchased from Pall Corporation (Port Washington, NY).
Immulon™ 2HB flat ELISA plates were from Thermo Scien-
tific (Marietta, OH). Mouse anti-morphine monoclonal anti-
body BD1263 was purchased fromAbcam (Cambridge, MA).
Peroxidase-linked sheep anti-mouse IgG (γ-chain specific)
was purchased from The Binding Site (San Diego, CA).
2,2′-Azino-di(3-ethylbenzothiazoline-6-sulfonate) (ABTS)
peroxidase substrate system was purchased from KPL, Inc.
(Gaithersburg, MD). Mass spectrometry grade water and ace-
tonitrile (ACN) were obtained from Fisher Scientific.
Dulbecco’s phosphate-buffered saline (DPBS, 10 mM
Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl,
pH 7.4), used for dialysis, was purchased from Quality Bio-
logical Inc. (Gaithersburg, MD).
Deprotection of MorHap
Deprotected hapten was obtained by dissolving trityl-
protected MorHap (6.0 mg) in chloroform (656 μL, 87.5 %),
treating with TFA (75 μL, 10 %) and TIS (19 μL, 2.5 %) for
1 h at RT, and concentrating the reaction mixture under high
vacuum overnight. The crude residue was solubilized in water
(1 mL) with sonication and was membrane filtered.
Coupling procedure described by Matyas et al. [6]
SM-(PEG)2 linker (6.0 mg) and BSA (2.5 mg) were incubated
in 1 mL DPBS. The molar conjugation ratio of the linker to
BSA was approximately 400. After stirring for 2 h at RT,
excess linker was removed by overnight dialysis in DPBS at
4 °C. An aqueous solution of MorHap (~1 mL) was added
dropwise to a stirring solution of dialyzed BSA-(PEG)2-
maleimide intermediate (maleimide-BSA). Following incuba-
tion at RT for 2 h, excess hapten was removed by overnight
dialysis DPBS at 4 °C. The BSA-(PEG)2-MorHap conjugate
(MorHap-BSA) was membrane filtered and the protein con-
centration was measured by BCA assay. The conjugation
route for the preparation ofMorHap-BSA conjugates is shown
in Fig. 1.
Optimization of the coupling procedure
SM-(PEG)2 linker (60 μL, 250 mM in DMSO) and BSA
(2.5 mg, 10 mg/mL in PBS) were incubated in 1 mL PBS
for 2 h at RT. The molar conjugation ratio of the linker to BSA
was 400. The linker was prepared as a DMSO stock solution
to avoid potential error in weighing small amount of reagents.
Excess linker was removed by either overnight dialysis
against DPBS or spin desalting column.
An aqueous solution of MorHap was prepared as described
above, but was purified prior to solubilization in water. Brief-
ly, the trityl side product of hapten deprotection was removed
by petroleum ether wash (500 μL, three times). The complete
removal of the side product was confirmed by thin layer
Fig. 1 Synthesis of MorHap-BSA conjugates using thiol-maleimide
coupling chemistry
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chromatography. MorHap was added dropwise to a stirring
solution of purified maleimide-BSA. Following incubation at
RT for 2 h, excess MorHap was removed by either overnight
dialysis at 4 °C or spin desalting column. The MorHap-BSA
conjugate was membrane filtered and the protein recovery
was determined by BCA assay.
Coupling procedure for the preparation of MorHap-BSA
with varying hapten densities
BSA (2.5 mg) was treated with different amounts of
SM-(PEG)2 linker (0.75, 1.50, 3.75, 7.5, 15, 30, or 60 μL of
250 mM in DMSO) and incubated in 1 mL PBS for 2 h at RT.
This corresponded to a linker ratio of 5, 10, 25, 50, 100, 200,
and 400, respectively. Excess linker was removed by spin
desalting column. Protein aliquots were taken to determine
the maleimide content of the activated BSA.
An aqueous solution of MorHap was prepared and washed
with petroleum ether as described above. In addition, the
amount of thiols in solution was measured by Ellman’s assay.
MorHap was added dropwise to a stirring solution of purified
maleimide-BSA. The different molar conjugation ratios of the
hapten to maleimide-BSA tested were 25, 100, and 400. The
volume of the mixture was equalized by adding PBS. Follow-
ing incubation at RT for 2 h, excess MorHap was removed by
overnight dialysis at 4 °C. The MorHap-BSA conjugate was
membrane filtered and the protein recovery from maleimide-
BSA to MorHap-BSA was determined by BCA assay. The
hapten equivalences/density was measured by the TNBS as-
say and MALDI-TOF MS.
Ellman’s assay
In the conventional Ellman’s assay, thiol concentration of the
sample is measured based on the standard curve of a water-
soluble thiol, MESNA. Briefly, a standard curve was prepared
by adding the Ellman’s reagent to different concentrations of
MESNA. An aliquot of MorHap was diluted in 100 mM
sodium phosphate buffer (PB), pH 8.0 (800 μL final volume)
and treated with Ellman’s reagent (160 μL, 10 mM in PB,
pH 8.0). The absorbance of the reaction mixture was read at
412 nm and the thiol concentration was quantified from the
standard calibration curve. The thiol concentration was used
to calculate for the molar conjugation ratio of MorHap to
maleimide-BSA.
Modified Ellman’s test
The modified Ellman’s test was used to measure the concentra-
tion of maleimide in the sample. Maleimide-BSAwas allowed
to react with excess MESNA. After the reaction, unreacted
MESNA was back titrated with Ellman’s reagent (Fig. 2a).
The difference between the initial and final MESNA
concentration corresponded to the maleimide content of the
sample. An aliquot of maleimide-BSA was suspended in PB,
pH 7.2, and subsequently, reacted with excess MESNA
(160 μL, 500 μM in PB, pH 8.0). The final volume and final
protein concentrations, [maleimide-BSA], of the reaction mix-
ture were 800 μL and 1 μM, respectively. The reaction mixture
was incubated at RT for 5 min. Ellman’s reagent (160 μL,
10mM in PB, pH 8.0) was added to the reaction and absorbance
was measured at 412 nm. The amount of unreacted MESNA,
[MESNA]final, was determined from a calibration curve. The
initial concentration ofMESNA, [MESNA]initial, was the excess
MESNA described above without the protein. The number of
maleimides per protein was calculated using the expression:
Number of maleimides ¼ MESNA½ initial− MESNA½ final
 
maleimide‐BSA½ 
Fig. 2 Indirect methods for measuring hapten density of protein conju-
gates. Modified Ellman’s test was performed by treating maleimide-BSA
intermediate with excess MESNA and subsequently back titrating the
unreacted MESNAwith Ellman’s reagent (a). TNBS assay was executed
by reacting MorHap-BSA conjugates with TNBS in basic buffer (b).
Both chemical assays measured hapten equivalences
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The number of maleimides represented hapten equiva-
lences since the maleimide group in maleimide-BSAwas the
reaction partner of MorHap.
TNBS assay
TNBS specifically reacts with primary amines to give a
yellow-colored product that can be monitored at 420 nm
(Fig. 2b). MorHap-BSA conjugates were suspended in
0.1 M NaHCO3, pH 8.0, and treated with TNBS (250 μL,
0.01% in 0.1 MNaHCO3). The final volume and final protein
concentration, [MorHap-BSA], of the reaction mixture were
500 μL and 1 μM, respectively. The reaction was incubated
for 2 h at 37 °C and the absorbance was measured at 420 nm.
The free amine concentration, [Amine], was calculated from
the corresponding calibration curve plotted using L-glutamic
acid as a standard. The number of amines per protein was
calculated using the expression:
Number of amines ¼ Amine½ 
MorHapBSA½ 
The difference in the number of free amines before and
after conjugation represented hapten equivalences because the
amino group reacts with the linker during the coupling
process.
MALDI-TOF MS
The mass of the MorHap-BSA conjugates was determined
using Axima MegaTOF™ (Shimadzu Scientific Instruments,
Columbia, MD). The Axima MegaTOF™ is capable of ultra
high mass analysis up to the megadalton level. Briefly, BSA
starting material and MorHap-BSA conjugates were desalted
using C4 ZipTip. The proteins (0.5 μL) were mixed with
(0.5 μL) sinapinic acid (10 mg/mL in 50:50 ACN/H2O
0.1 % FA) and spotted on a MALDI-TOF 384-well stainless
plate. The protein-matrix samples were allowed to crystallize
at RT. Prior to measurements, the instrument was calibrated
against BSA MALDI-TOF calibration standard. Hence, the
ionization of the MorHap-BSA conjugates was expected to be
similar and any mass shift was attributed to hapten incorpo-
ration into the protein. Mass spectra of BSA starting material
and MorHap-BSA conjugates were acquired by averaging
500 mass profiles in the linear mode. Mass spectra were
smoothed using the Gaussian method and mass assignments
were done using threshold apex peak detection. The number
of the haptens was calculated using the expression:
Number of haptens ¼ MassMorHapBSA− MassBSA
MassMorHaplinker
The net mass addition of MorHap and linker,
MassMorHap-linker, was 682.27 g/mol.
ELISA
MorHap-BSA conjugates of varying hapten density (0.1 μg
BSA in 100 μL of DPBS) were added to the ELISA plates and
incubated at 4 °C overnight. The remainder of the ELISAwas
performed as described [5, 6]. Briefly, the plates were blocked
with 1 % BSA in 20 mM Tris-0.15 M sodium chloride,
pH 7.4, for 2 h. Mouse sera and mouse anti-morphine mono-
clonal antibody were diluted in blocker and added to the
plates. Mouse sera were obtained from Balb/c mice immu-
nized with MorHap-TT conjugates from the study of Matyas
et al. [6]. Following incubation for 2 h at RT, the plates were
washed with 20 mM Tris-0.15 M sodium chloride-0.05 %
Tween 20®. Peroxidase-linked sheep anti-mouse IgG diluted
in blocker was added and the plates were incubated for 1 h at
RT. The plates were washed and ABTS peroxidase substrate
system (100 μL) was added. After incubation at RT for 1 h,
1 % SDS (100 μL) was added to stop the reaction and the
absorbance was read at 405 nm.
Data analysis
Statistical analysis was performed using GraphPad Prism. A T
test (unpaired, one tail) was used for comparison of maleimide
content. A one-way ANOVAwith Dunn’s correction for mul-
tiple comparisons was used to compare the effect of the
purification steps on protein yield and the effect of hapten
density to ELISA absorbance. A two-way ANOVA with
Tukey’s correction for multiple comparisons was used to
compare the direct and indirect methods for quantifying hap-
ten density, the effect of MorHap:maleimide-BSA ratios on
protein yield, and the effect of MorHap ratios on hapten
density.
Results and discussion
Optimization of protein yield and number of maleimides
The thiolated MorHap was conjugated to BSA in a two-step
reaction using SM-(PEG)2. Surface lysines of BSAwere first
reacted with the NHS ester end of the linker to give an
activated maleimide-BSA intermediate. The subsequent step
used the Michael addition of MorHap to maleimide end of the
BSA intermediate. Using the coupling procedure described by
Matyas et al., the MorHap-BSA conjugate was obtained with
only a 5–10 % yield [6]. This poor yield may be due to the
precipitation of the BSA conjugate due to the addition of
unpurified hapten. Since BSA binds fatty acids [24], it was
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plausible that the binding of the BSA conjugates to the free
trityl side product decreased the water solubility of the BSA.
When the trityl side product was removed by a petroleum
ether wash after the deprotection of MorHap, the yield of the
conjugate was improved to 20–25 %.
Purification of protein conjugates has been an important
prerequisite in method development [25]. The effects of the
two purification steps, purification after linker addition and
purification after hapten addition, on the protein yield of the
MorHap-BSA were investigated. Briefly, BSA was treated
with a 400-fold molar excess of the SM-(PEG)2. The protein
yield of the maleimide-BSA was not significantly different
between the desalting column or dialysis procedures (Fig. 3a).
Since the number of maleimides corresponds to the number of
haptens attached, the selection of the purification method was
not only dependent on the protein yield, but also on the
maleimide content of the BSA. Overnight dialysis of the
activated BSA led to the loss of approximately 20 % of the
maleimide compared to the column-purified maleimide-BSA
(Fig. 3b). Although the apparent rate of hydrolysis of
maleimide to maleamic acid was slow [26], its cumulative
degradation became pronounced over the 14–18 h of dialysis.
The effect of the method of purification on the protein yield
after hapten addition was also investigated. The protein yield
of MorHap-BSA was significantly decreased when desalting
columns were used for purification compared to dialysis
(Fig. 3c). The decrease in the protein yield suggested that
covalent attachment of the hapten increased the overall hy-
drophobicity of MorHap-BSA conjugate. This was confirmed
by the observation that the maleimide-BSA solutions became
cloudy after hapten addition. This suggested that the MorHap-
BSA conjugate aggregated and either did not pass through the
column resin or also adhered to the column, thereby, reducing
the protein yield. A similar loss of protein yield was not
observed in the column purification of maleimide-BSA be-
cause the decrease in the positive charge of BSA after linker
conjugation was compensated by the introduction of the hy-
drophilic PEG chain. Based on the protein yield and the
number of maleimides, the column and dialysis purification
methods were chosen as the first and second purification
procedure, respectively. Furthermore, the combination of the
two purification procedures decreased the time of the overall
synthesis procedure from 3 to 2 days.
Our initial work on optimization suggested that the number
of haptens covalently attached to BSA and the concentration
of unreacted haptens in solution may influence protein yield.
SinceMorHap is a hydrophobic hapten, BSAwith 35MorHap
molecules attached was less soluble in water than BSA with
fewer haptens. The solubility of BSAwith 35 MorHap mole-
cules attached also may be different in the presence of excess
unreacted haptens. The coupling procedure was further ex-
plored by examining the effects of hapten density and excess
hapten in solution on protein yield.
Molar ratio of linker to BSA dictates hapten density
To accurately dissect the relationship between hapten density
and protein yield, MorHap-BSAwith varying hapten densities
was synthesized. Briefly, BSAwas treated with an increasing
molar conjugation ratio of SM-(PEG)2 linker: 5, 10, 25, 50,
100, 200, and 400. After column purification, the maleimide-
BSA intermediates were treated with 400-fold molar excess of
MorHap. Precipitates were not observed when MorHap was
added to maleimide-BSA derived from 5, 10, 25, 50, and 100
molar ratio reactions. In contrast, an opaque mixture and solid
aggregates were observed for 200 and 400 molar ratio reac-
tions, respectively. Thus, MorHap-BSA conjugates with low
hapten densities were more soluble in aqueous environment
than MorHap-BSA conjugates with high hapten densities. To
verify if these observations were due to an increase in hapten
density, the masses of the dialyzed conjugates were measured
by MALDI-TOF MS. Mass spectra overlays revealed distinct
peaks for each molar conjugation ratio (Fig. 4). Using
MALDI-TOF MS, M+H+ and M+H2+ for each unique con-
jugates were detected in acceptable relative intensities. More-
over, no oligomeric forms of MorHap-BSA conjugates were
Fig. 3 Effect of purification steps on protein yield and maleimide con-
tent. BSA was treated with 400-fold molar excess of the SM-(PEG)2.
Excess linker was removed by either spin desalting column or dialysis
(first purification). The protein yield and maleimide content of
maleimide-BSAwas determined by BCA (a) and modified Ellman’s test
(b), respectively. The number of maleimides statistically decreased after
overnight dialysis (**p<0.01, T test). The combined effect of the two
purification steps on protein yield was assessed by BCA (c). The yield of
MorHap-BSA was significantly decreased in the second column purifi-
cation (*p<0.05, one-way ANOVA). Values are the mean of three inde-
pendent experiments±standard deviation
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observed in the mass spectra. Since all M+H+ peaks exhibited
Gaussian profiles, accurate mass measurements can be made
for the MorHap conjugates [27]. MorHap-BSA conjugates
with 3, 5, 10, 15, 22, 28, and 34 haptens were obtained using
linker to BSA ratios of 5, 10, 25, 50, 100, 200, and 400,
respectively. Although hapten density is dependent on the
molar ratio of linker to BSA, the relationship between the
two was not linear. For example, the linker ratio of 25 did not
translate to 25 haptens due to steric hindrance associated with
the coupling reaction and the inherent reactivity of
SM-(PEG)2 in aqueous buffer. At physiological pH, water
and surface lysines compete for the NHS ester end of the
linker, while the maleimide end hydrolyzes to maleamic acid.
Thus, the actual hapten density must be determined empiri-
cally for any given linker to BSA ratios.
Comparison of methods for quantifying hapten density:
MALDI-TOF MS, TNBS assay, and modified Ellman’s test
The hapten densities that were measured byMALDI-TOFMS
were compared to modified Ellman’s test and TNBS assay.
Hyperbolic shapes were observed for the three quantification
curves indicative of limited attachment sites (Fig. 5a). The
quantification curves revealed that the maximum number of
haptens that can be attached in BSA was 34–35, which was
consistent with the number of surface lysines (30–35) in
native BSA [12]. Congruent results also were observed for
the modified Ellman’s test and MALDI-TOF MS. These two
methods gave the same number of haptens for all the seven
MorHap-BSA conjugates and suggested that under optimum
reaction conditions, hapten equivalences were similar to hap-
ten density.
The results of TNBS assay were also comparable to
MALDI-TOF MS and modified Ellman’s test for MorHap
conjugates with 29 and 34 haptens attached. However, the
TNBS assay overestimated the number of haptens for
MorHap conjugates in the 3–22 hapten range. Interestingly,
Adamczyk et al. also observed an overestimation of covalent-
ly attached haptens for hapten-BSA conjugates with TNBS
[14]. This may be due to conformational changes induced in
the protein and/or a masking effect of the nonmodified lysines
by the neighboring haptens obstructing the reaction between
nonmodified lysines and TNBS. This resulted in an underes-
timation of the remaining free surface amines on BSA, there-
by, giving an overestimation of the number of haptens at-
tached. The overestimation of hapten density by the TNBS
assay could be also due to maleimide hydrolysis. Using the
modified Ellman’s test, active maleimides were not observed
in the MorHap-BSA conjugates, which suggest complete
quenching by the hapten or maleimide hydrolysis. The ab-
sence of active maleimides in MorHap-BSA conjugates is
most likely due to hapten coupling since the maleimide-thiol
reaction is significantly faster than the hydrolysis of
maleimide to maleamic acid [26].
In terms of the amounts of the sample required and the ease
of experimental set-up, MALDI-TOF MS was superior to the
two chemical strategies. Since the TNBS assay and the modi-
fied Ellman’s test were both colorimetric methods, large
amounts of proteins and freshly prepared reagents were needed
for reliable results. In contrast, MALDI-TOFMS only requires
removal of salts from small amounts of sample by ZipTip.
Using MALDI-TOF MS, the modified Ellman’s test and the
TNBS assay, the synthesis of reproducible MorHap-BSA con-
jugates with different hapten densities was established.
Molar ratio of the hapten is crucial for the preparation of high
density MorHap conjugates
Through the use of MALDI-TOF MS, the TNBS assay, the
modified Ellman’s test, and the BCA assay, the relationship
between hapten density and protein yield was demonstrated.
Specifically, the low yield of MorHap-BSAwith high density
Fig. 4 MALDI-TOF mass
spectra of MorHap-BSA
conjugates with varying hapten
densities. The representative
MALDI-TOFmass spectra for the
seven MorHap-BSA conjugates
were overlaid with the mass
spectrum of unreacted BSA. The
number of haptens attached to
BSAwas directly proportional to
linker:BSA molar ratios
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(34–35 haptens) was due to its limited solubility in aqueous
buffer. Since the normal function of BSA is to bind fatty acids,
it was also possible that the unreacted haptens in solution
bound noncovalently to MorHap-BSA conjugates. Thus, the
excess unreacted MorHap would be expected to lower the
yield of the reaction by further decreasing the solubility of the
MorHap-BSA conjugates. The effect of the hapten to
maleimide-BSA ratios on protein yield was investigated by
treating seven different maleimide to BSA linker ratios with
three different hapten ratios: low (25), intermediate (100), and
high (400). The protein yield of the resulting 21 MorHap
conjugates was determined by BCA (Fig. 5b). When the
maleimide-BSA linker ratio of 400 was treated with a 25,
100, and 400 molar conjugation ratio of MorHap, a solution,
an opaque mixture, and solid aggregates were observed, re-
spectively. Almost full recovery of the protein was obtained
when maleimide-BSA was treated with a low hapten ratio
(25:1), 74% of the protein was recovered with an intermediate
ratio (100:1), and approximately 48 % of the protein was
rescued at a high hapten ratio (400:1). The protein yields were
significantly higher compared to the yield of 5–10 % obtained
from the initial unoptimized method. The improvement in
yield might be due to the rigorous assays that we employed
prior to the coupling of maleimide-BSA toMorHap. Accurate
MorHap to maleimide-BSA ratio was achieved by measuring
actual protein and thiol amounts by BCA and Ellman’s assay,
respectively. The actual MorHap to maleimide-BSA ratio
might have been higher than expected in our previous exper-
iments, which results in lower protein yield.
The effect of the hapten to maleimide-BSA ratio (25, 100,
and 400) was evaluated in terms of hapten density. Equal
portions of themaleimide-BSA intermediate were subsequently
Fig. 5 Effect of linker and hapten ratios on hapten density and protein
yield. Comparison of direct and indirect methods for quantifying hapten
density/equivalences (a). There was no significant difference in the
number of haptens quantified by modified Ellman’s test and MALDI-
TOF MS in all linker:BSA conjugation ratios. TNBS overestimated the
number of haptens at 5, 10, 25, 50 (p<0.0001, two-way ANOVA), and
100 (p<0.01, two-way ANOVA) linker:BSA molar conjugation ratios.
Effect of hapten ratios on the yield of MorHap-BSA conjugates (b). The
protein yield was significantly different at linker:BSA molar ratio of 400
(****p<0.0001, two-wayANOVA). Effect of hapten ratios on the hapten
density of MorHap-BSA conjugates (c–i). TNBS overestimated the num-
ber of haptens at low linker:BSA conjugation ratios similar to Fig 5a
(**p<0.01 and ****p<0.0001, two-way ANOVA). There was no signif-
icant difference in hapten density when maleimide-BSA intermediates
obtained from 5, 10, 25, 50, 100, and 200 linker:BSA ratios were treated
with 25-, 100-, and 400-fold molar excess of MorHap. Subtle differences
in hapten density were detected by MALDI-TOF MS at 400 linker:BSA
ratio (*p<0.05 and ****p<0.0001, two-way ANOVA). Values are the
mean of three independent experiments±standard deviation
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treated with 25-, 100-, and 400-molar-fold excess ofMorHap to
give three MorHap conjugates for each linker ratios (Fig. 5c–i).
Analogous to our previous results, the TNBS assay
overestimated the results for conjugates with linker to BSA
ratios of 5–100 (Fig. 5c–g) while MALDI-TOF MS, modified
Ellman’s test, and TNBS assay gave comparable results for the
high-hapten-density conjugates (Fig. 5h, i). However, only
MALDI-TOF MS was able to discriminate subtle differences
in hapten density. MorHap-BSA conjugates derived from
maleimide-BSA (34–35 linkers) treated with 100- and 400-
fold molar excess of the hapten were statistically increased
compared to the MorHap-BSA conjugate that was obtained
with 25-fold molar excess of the hapten (Fig. 5i).
Hapten concentration was pivotal for the preparation of
BSA conjugates with high hapten density. A low hapten to
maleimide-BSA ratio resulted in high protein yield (~100 %),
but a lesser number of haptens attached (32). While a high
hapten to maleimide-BSA ratio translated to poor protein yield
(49 %), but a higher number of haptens attached (34). These
data suggest that the intermediate molar conjugation of 100 is
the optimal hapten to carrier ratio (74 % yield, 35 haptens
attached). In terms of thiol-maleimide coupling chemistry, this
corresponds to a 3:1 thiol to maleimide ratio. For the synthesis
of MorHap-BSA with varying hapten densities, the optimum
procedure involved purification of maleimide-BSA by spin
desalting column, purification of the deprotected hapten by
petroleum ether washing and subsequent quantification of the
thiol concentration by Ellman’s assay, treatment of maleimide-
BSAwith 100-fold molar excess of the hapten, and purification
of the final MorHap-BSA conjugates by dialysis.
MorHap-BSA conjugates with lower hapten densities bound
higher amounts of antibodies
Antigen-antibody interactions are crucial in ELISA [28–31].
Antigen-antibody interfaces are primarily controlled by
hydrophobic [32] and electrostatic interactions [33], as well
as steric effects [28, 34]. MorHap-BSA conjugates with a
varying number of haptens were evaluated for their ability to
detect antibodies against MorHap [5, 6]. MorHap conjugates
with lower hapten densities had higher ELISA absorbances
than conjugates saturated with haptens (Fig. 6). These results
are consistent with the five mouse sera (Fig. 6a–e) and a
monoclonal IgG to morphine (Fig. 6f). ELISA absorbance
decreased as hapten density increased at both sera dilutions
(1:50,000 and 1:100,000).
We anticipated that BSAwith 34 conjugated haptens would
give the highest ELISA absorbances because it contains nu-
merous binding sites for the antibody. However, it is possible
that the difference in ELISA absorbances was due to the
difference in the binding interactions of the MorHap-BSA
conjugates to the ELISA plates. Electrostatic effects cannot
account for the difference in the ELISA absorbances, since the
zeta potential of the conjugates are comparable at physiolog-
ical pH (Electronic Supplementary Material, Fig. S1). The net
charge of the conjugates, which can be correlated to zeta
potential, is similar since the depletion of lysine’s positive
charge (pKa=10.53) after hapten conjugation is restored by
MorHap’s tertiary amine (pKa=8.2). Likewise, the hydropho-
bicity of MorHap-BSA conjugates cannot explain the differ-
ence in ELISA absorbances since the contact angles of the
protein conjugates were equivalent (Electronic Supplementa-
ry Material, Table S1). There may be small differences in the
binding of MorHap-BSA conjugates to the ELISA plates.
However, there are no known sensitive assays to detect these
small differences.
Steric effects could possibly explain the drop in absorbance
with increasing hapten density. A molecule of IgG contains
two fragment antigen-binding (Fab) moieties with 4 nm base
that are separated by 10–15 nmdistance [35–37]. Based on the
crystal structure of BSA, a molecule was reported to be
ellipsoid with dimensions of 8×4 nm [38]. In addition, both
Fig. 6 Effect of hapten density
on ELISA absorbance. Mouse
sera from different animals (a–e)
and monoclonal IgG to morphine
(f) were assayed against MorHap-
BSA conjugates with different
hapten densities. Mouse sera
dilutions were 1:50,000 (closed
circles) and 1:100,000 (open
circles). The asterisk indicates
that values were significantly
different (p<0.05, one-way
ANOVA) compared to the highest
hapten density (34) group. Values
are the mean of triplicate
determinations±standard
deviation
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the crystal structure and the homology model indicated
that surface lysines of BSA were in close proximity
[39]. This implies that the surface area of BSA where
the haptens were attached is densely packed. This sug-
gests that there is binding penalty to the approaching
antibody due to steric effects associated with the “hap-
ten cluster” and antigen-binding site. Based on the
above, a hapten-BSA molecule would be expected to
accommodate only one Fab moiety of two to five dif-
ferent IgG molecules. The ELISA results indicated that
MorHap-BSA conjugates with three to five haptens gave
the highest antibody binding and therefore, should be
used as the ELISA plate-coating antigen to yield the
maximum sensitivity of the assay.
Conclusion
In summary, this study describes the optimization of a
coupling procedure for the synthesis of MorHap-BSA
conjugates, which would also be applicable to other
thiol-based haptens. The study also demonstrated that
MorHap-BSA conjugates with a hapten density gradient
could be synthesized in good yields using different
mola r - fo ld excess of the l inker and op t ima l
hapten:maleimide-BSA molar conjugation ratios. In ad-
dition, the number of haptens per molecule of carrier
could be accurately measured by MALDI-TOF MS. The
modified Ellman’s test and TNBS assay are also useful
for determining the number of haptens attached. Using
the optimized and quantitative coupling procedure,
MorHap-BSA conjugates were produced with high re-
producibility. In ELISA, MorHap-BSA conjugates with
varying hapten densities were used as coating antigens.
The data indicated that lower hapten density conjugates
bound higher amounts of antibodies. This suggests that
similar hapten conjugates must be prepared with consis-
tency for ELISA sensitivity and the quantification of the
haptens bound to the carrier is critical for reproducibil-
ity. The synthetic procedures and the analytical tech-
niques that are described in this study will also be
useful in the preparation and characterization of other
hapten-protein conjugates for vaccine development and
assay.
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